Clinical Trial Update: A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating DB-1303/BNT323 versus investigator's choice chemotherapy in HER2-low, hormone receptor–positive metastatic breast cancer is active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DB-1303/BNT323

Snippet

Sponsor: DualityBio Inc. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING